A.J. Rice

Joel said the economics are immaterial near-term and already in 2026 guidance, with the mortality-driven benefit not expected to begin until 2028.

Joel characterized both items as minor swings within a few basis points, nothing material to the full-year outlook.

CFO confirmed cost movements were normal seasonal patterns, particularly the Q4-to-Q1 decline in health benefits. Nothing unusual in the quarter's cost structure.

CEO framed technology investments as supporting long-term 3-7% OI growth sustainability. Some investments enhance user experience, others will flow to the bottom line. Declined to give specific timing or sizing.

CEO confirmed no observable shift yet in disease progression or time on dialysis from GLP-1s or improved CKD management. Effects take time to manifest; DaVita has only managed CKD populations for about 5 years.

CEO described dual thesis: financial return on capital plus clinical value. Approximately 25% of DaVita patients use home health; specialized ESKD protocols through Elara could reduce hospitalizations, readmissions, and missed treatments.

CFO confirmed the Mozarc charge largely eliminates the P&L drag for next year, but it flows through other income, not OI. Cyber impact in Q3 and Q4 is primarily volume-related and much smaller than Q2; cost side has been non-GAAPed.

CFO bridged the ~$60M Q3-to-Q4 OI increase needed: ~$30M seasonal cost headwind offset by ~$15M day mix volume tailwind, ~$25M IKC timing, and ~$50M RPT improvement from vaccines, rate increases, and aged claims resolution.

CFO confirmed it was timing of 2024 plan year shared savings recognized earlier than expected. Total annual revenue unchanged, so it is genuinely a pull-forward, not incremental.

CFO explained two components: larger impact from delayed prior authorizations and data gathering on Q2 claims; smaller impact from older denied claims becoming harder to collect as time passes.

CFO confirmed the IT product reallocation ($4M/quarter from IKC to US other ancillary) has no enterprise impact. Still feels good about the path to IKC profitability.

CEO indicated Brazil deal nearing completion but requires divesting a couple of centers. Internationally continues to be interesting; domestically pursuing smaller deals and practice conversions.

No specific buyback figure given. CFO noted potential for hundreds of millions in M&A but nothing that would significantly change the repurchase program.

CFO broke down 6.5% midpoint into 3.75% from historical costs and 2.75% from orals, with labor and non-labor growing at similar rates.

Filton disclosed that the assumed 10-20% migration to employer coverage did not occur, which drove the exchange impact estimate up $10 million.

Filton gave a structured answer across expense control, technology and revenue cycle work, and reducing Medicaid mix through outpatient growth.

Filton gave brief response that core acute EBITDA growth was in the low single-digit range. Miller said AI focus is on administrative efficiency (8 revenue cycle use cases live) and clinical operations for patient experience, not yet in core clinical decision space.

Filton said acute pricing 3-4% in line with 10-year average, supported by steady acuity increases. Behavioral pricing 2-3%, acknowledging moderation from recent years' 4-5% as strong contract prices begin to anniversary.

Filton said early innings of AI with focus on revenue cycle and post-discharge. Driving headcount efficiencies and improved outcomes. Acknowledged difficult to precisely quantify current achievements or future opportunities but considers them significant.

Filton said Q3 acute pricing of ~5% ex-DPP was elevated by revenue cycle initiatives and small one-timers; sustainable level is 3%+. Behavioral pricing sustainable at 3.5-4.5%, with current 4-5% at high end due to capacity scarcity.

Filton confirmed $18M litigation settlement booked in Q3 non-same-store acute. Additional $25M miscellaneous DPP spread ratably between Q3 and Q4.

Filton said behavioral pricing remains strong due to capacity scarcity. Payer aggressiveness in day-to-day revenue cycle is an ongoing challenge but not incrementally worse. UHS investing in process improvements.

Filton split the $380M OBBA impact as 60% behavioral / 40% acute. DC program still pending with the District having ongoing CMS conversations. New programs still allowed under the bill.

Filton said Texas and Florida are already below 6% so impact would be limited in key states. Detailed calculation is complex and companies are reserving estimates.

Filton said UHS has not seen material base Medicaid rate reductions linked to DPP offsets, though acknowledged it could happen in the future.

Filton explained 5% of acute admissions are exchange patients, assumed half would lose coverage, losing the elective business while retaining emergency visits unreimbursed.

Filton acknowledged some same-store cannibalization from West Henderson and Cedar Hill but said both are expected to be combined EBITDA positive in 2025.

Tim Noel said commercial trends are stabilizing at high levels, 2027 pricing assumes they persist, and the long-term commercial margin target will take longer.

Hemsley reaffirmed the 13%-16% algorithm and framed the turnaround as ongoing rather than complete, but gave no dated commitment for reaching the range.

Tim Noel confirmed modest favorability in government programs including MA, with commercial in line. Pricing assumption of 10% into 2026 tracking, with elevated utilization continuing at high levels from 2025. No inflection point seen.

Hemsley declined to speak to 2027 specifically but expressed strong confidence in longer-term 13-16% growth rate. Cited organic growth, AI-driven productivity, OptumInsight platform potential, value-based care need, and capital stewardship as drivers. Said long-term growth potential for enterprise more compelling than ever but requires execution.

Dadlani highlighted Optum Real as first real-time claims platform in industry. Optum Integrity One AI auto-coding showing 73% productivity improvement for ambulatory outpatient and 23% for hospital inpatient. Crimson AI clinical analytics platform won 6 deals in 90 days with 13:1 ROI. Traditional services must evolve to AI-first services then products then platforms.

Conway confirmed UHC repricing flows into Optum Health capitation rates as a tailwind for 2026. Combined with benefit reductions and operating cost discipline expects to mitigate 50% of remaining $4 billion V28 headwind. 2026 VBC margins expected to remain at approximately 1% before advancing in 2027.

Noel confirmed elevated care activity focused on community and group MA, not chronic SNP or dual eligible. Slightly more pronounced on group side but community MA also elevated. Prior year concerns of provider upcoding and specialty drug pressure tracking in line with plan.

Rex said Q4 trends stabilized at Q3 levels, not accelerating. Sequential MCR move driven by typical seasonality (deductible wear-off) plus 80-90bps of non-run-rate revenue effects including group MA refunds. Flu/RSV impact 50-60bps, typical seasonal.

Brian confirmed high-single-digit cost trends with slight outpatient favorability that is not a trend break; Ann said risk adjustment confirmed expectations and was not a Q driver. Direct.

Brian provided comprehensive detail on Signature model timeline, confirming 50%+ PBS member adoption target by year-end 2028 and strong 2027 selling season with key new business wins already secured.

David confirmed no change in direction from FTC settlement or legislation, model designed in early 2025 was congruent with regulatory trajectory. Manufacturer recontracting is familiar work. Formulary changes not directly correlated to model transition, still governed by clinical efficacy.

David declined to confirm specific 2026 EPS growth rate but noted 2026 cash flow will be back-end loaded similar to 2025, and company will balance share repurchase and deleveraging. On rebate-free adoption, this will be standard offering with consultative transition approach for employers wanting alternative models.

David highlighted pharmacy now 25%+ of total healthcare cost (up from 10-12% a decade ago), growing toward 30%. Brian noted specialty and mental health as largest trend drivers, with Evernorth insight helping manage Cigna Healthcare MCR.

Brian reported mid-90s+ PBM retention for 2026, national accounts flat to shrinking market with share maintenance strategy. Select growth driven by funding-agnostic model, not economic cycle.

Brian walked through normalized FY2024 Cigna Healthcare earnings slightly below $4B after removing Medicare, stranded overhead, and prior year development as basis for 2025 comparison.

London described simplification, operating model changes and AI-enabled modernization but did not quantify the G&A ratio benefit from the optimization program.

Sarah confirmed flu and weather were bigger pieces of Q1 outperformance but solid fundamental execution also contributed via network optimization, clinical programs, payment integrity, and fraud initiatives. Pipeline of 2026 initiatives developed earlier than expected. Forecasting rest of year does not count on continued outperformance but fundamental drivers lean positive. Goal to continue progressive margin improvement through 2027.

Sarah emphasized elevated baseline jump-off from 94.9% Q2, favorable rate maturation in 2025, and aggressive back-half execution with sequential HBR improvement to 93%. Drew noted $60B pharmacy spend with tailored transparent PBM contract predating legislative mandates, with all economic benefit flowing into insurance risk segments.

Sarah outlined multi-layered enrollment preparation including broker mobilization and marketing for potential special enrollment period. Even with eAPTC extension, expects some breakage driving high-teens to mid-30s market contraction. Work requirements pushed to 1/1/27 in all early states.

Sarah explained the key insight was that members shed by other carriers left the market entirely rather than switching, creating a systemwide morbidity shift not visible in their own data alone.

Sarah confirmed ~$1/share APTC headwind estimate unchanged. Work requirements not new, already in some states, expect high variability in implementation.

Sarah confirmed stable Medicaid trends, felt good about Q4 run rate medical expense. Drew noted Medicare outperformance driven by PDP.

Mark confirmed H2 Medicaid margin improves on favorable July rate activity and cost execution, but the exits were left unsized.

Gail detailed strong 2027 pipeline at near-record levels with early wins, employers focused on affordability and experience. Mark added Carelon Rx had national account wins and total sales running ahead of plan.

Mark provided detailed cost trend outlook by segment: commercial large group elevated but stable, ACA accelerating as subsidies expire, Medicaid at roughly twice historical average but some moderation expected, Medicare higher reported trend driven by D-SNP mix. Q4 overall in line to slightly better.

Mark framed two anchors: trend (2026 assumption anchored to Q4 exit rate as seasonal low point) and rates (modestly above historical but still trailing trend). Confirmed FY2025 Medicaid operating margin approximately negative 50bps. Felicia noted states are more receptive to program changes including ABA and GLP-1 modifications.

Mark confirmed guidance cut slightly more weighted to ACA than Medicaid. Gail noted they are not betting on trend improvement, embedding elevated morbidity and potential Q4 utilization surge.

Mark confirmed Medicare costs elevated but manageable, consistent with Q4. Flu and respiratory illness caused slight temporary uptick that moderated by quarter end.

Felicia confirmed AEP results aligned with expectations, driven by strong retention and balanced HMO growth. Mark indicated margin stability positioning for 2025.